Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston blog main
drugs
life sciences
national blog main
new york blog main
new york top stories
3
×
akcea therapeutics
biotech
boston
boston top stories
clinical trials
fda
hereditary transthyretin amyloidosis
inotersen
national top stories
patisiran
regeneron pharmaceuticals
rna interference
san diego blog main
san diego top stories
tafamidis
alirocumab
amgen
barry greene
boston university
dan ollendorf
european medicines agency
evercore isi
evolocumab
harvard pilgrim health care
heart attack
inclisiran
institute for clinical and economic review
john berk
joseph swartz
mary o'donnell
medicines co.
new york
onpattro
What
alnylam
3
×
rna
3
×
drug
fda
medicine
uses
ago
approve
approves
awaits
based
biological
cells
cholesterol
crossed
data
decades
decision
discovered
ema
employ
europe
evidence
fingers
follows
friday
gene
harmful
heart
historic
hits
interference
lasting
long
looms
lowering
make
medco
medicines
method
Language
Current search:
rna
×
alnylam
×
" new york top stories "
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision